ArticleSurgical endoscopy2026
Long-term oncologic outcomes after transanal total mesorectal excision: a single-center cohort with a minimum of 5-year follow-up.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransanal total mesorectal excision (TaTME) has gained increasing popularity for low to mid rectal cancer. Several studies have reported on short-term oncological outcomes and safety of this procedure, however, data regarding long-term outcomes are sparse. We aimed to evaluate the long-term oncologic and survival outcomes of patients who underwent TaTME at our center.
methodsThis study is based on our prospectively maintained TaTME database. We only included patients who had a minimum follow-up of five years. The primary endpoints were incidence of local recurrence (LR), distant recurrence (DR), overall survival (OS), and disease-free survival (DFS). Secondary endpoints included pathological outcomes and postoperative complications. We used the reverse Kaplan Meier method to calculate follow-up time, and the cumulative incidence function to calculate the probability of LR and DR, accounting for competing risks and avoiding biased estimation. We calculated subdistribution hazard ratios (SHRs) to assess the association between clinically relevant patient, disease, and pathology variables and disease recurrence (LR and DR separately).
resultsA total of 220 patients were included (160 male patients). At the time of analysis, 60.91% were alive, and 58.6% were alive and disease free. The incidence of LR at five years was 4.55%, and the incidence of DR was 15.94%. Anastomotic leakage was the only predictor of LR (SHR: 4.01, P = 0.012), while both pathologically positive nodal status and anastomotic leakage were significant predictors of DR (SHR: 3.58, P = 0.001 and SHR: 3.91, P = 0.008, respectively).
conclusionWe observed acceptable oncologic and survival outcomes following TaTME. Anastomotic leakage emerged as the strongest predictor of disease recurrence, underscoring the importance of meticulous surgical technique and optimal perioperative care in improving long-term oncologic outcomes.
Indexed as
Identifiers
42661067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.